1. EMA Note for Guidance on Quality of Modified Release Products: A: Oral Dosage Forms B: Transdermal Dosage Forms, 2000.
2. EMA, Guideline on the investigation of bioequivalence, January 2010.
3. FDA Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2003.
4. FDA Guidance for Industry Nonsterile Semisolid Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In vitro Release Testing and In vivo Bioequivalence Documentation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) May 1997.
5. ICH Steering Committee, Draft consensus guideline on development Q8 step 4, August 2009.